Paul Richardson
Doctor; discussed integration of novel therapies and the management of relapsed refractory myeloma.
Best podcasts with Paul Richardson
Ranked by the Snipd community
Aug 5, 2022 • 9min
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
Experts discuss integrating BCMA-directed agents in MM treatment, challenges of CAR T-cell availability, potential of bispecific therapies, and ADCs. Emphasis on managing keratopathy, high response rates with combination therapies, and the importance of evaluating BCMA-directed agents in earlier lines of therapy.
Dec 20, 2024 • 1h 57min
Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia Series
In this engaging discussion, Prof. Philippe Moreau from France, Dr. Robert Z Orlowski from MD Anderson, Dr. Noopur Raje from Massachusetts General, and Dr. Paul G Richardson delve into the complexities of managing multiple myeloma. They tackle innovative treatment strategies, including the use of CD38 antibodies, novel therapies, and the importance of minimal residual disease as a prognostic marker. The conversation also covers challenges in treating elderly patients, the role of CAR T-cell therapies, and the potential of the new BELLA drug in improving outcomes.
